It’s been just revealed that Moderna said that it’s expecting to report data from their vaccine trial in kids aged 2 to 5 in March.
“If the data is supportive and subject to regulatory consultation, Moderna may proceed with regulatory filings for children 2-5 years of age thereafter.”
It’s been also revealed that Moderna’s vaccine is based on the messenger RNA platform, and it already has authorizations in Europe, UK, Australia, and Canada for adolescents aged 12-17 years. It is also important to note the fact that the company has submitted applications for children in 6 to 11 years.
In the United States, the vaccine is authorized by Food and Drug Administration as a primary two-dose regimen and booster dose for adults 18 years and older. The company still has to get authorization from the regulator for use of its vaccine in children.
Covid in the news
The novel coronavirus and the disease that it can trigger, covid 19 have been making headlines a lot since 2020.
Just to refresh your memory, the new covid variant called Omicron has been making headlines all over the news for a while now, even though the symptomatology is a mild one.
More than that, it’s been also revealed that the original shots have also lost some of their efficacy at preventing hospitalization.
There’s something that triggered massive backlash for the CEO. It’s also important to note what he was saying back in 2021 about the vaccine’s efficiency:
Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa. 100%! https://t.co/E2ksTJSopU
— Albert Bourla (@AlbertBourla) April 1, 2021
Stay tuned for more news, and make sure to stay safe as well.